Microneedle particles and method for manufacturing microneedle particles

Abstract

The present invention relates to microneedle particles and methods for producing microneedle particles.

Description

Technical Field

[0001] The present invention relates to micronized needle particles and a method for producing the same.

Background Art

[0002] Drugs and physiologically active substances are generally administered orally in the form of tablets or capsules. However, many drugs cannot be effectively delivered only by the above administration method due to digestion or absorption in the gastrointestinal tract, or disappearance due to the mechanism of the liver. Furthermore, some drugs cannot effectively diffuse through the intestinal mucosa. In addition, patient compliance is also a problem.

[0003] Another common technique for delivering drugs and physiologically active substances is to use a conventional injection needle. This method is more effective than oral administration, but has problems such as pain at the injection site, local damage to the skin, bleeding, and infection of diseases at the injection site.

[0004] To solve the problems of oral administration and subcutaneous injection described above, a transdermal administration method using a patch is used. Transdermal administration using a patch has few side effects, high patient compliance, and is easy to keep the blood concentration of the drug constant.

[0005] For transdermal administration as described above, various microstructures such as microneedles have been developed. As materials for microneedles, metals and various polymer substances have been used. Recently, biodegradable polymer substances have been in the spotlight as materials for microneedles.

[0006] Such microneedles are manufactured in a patch shape with an adhesive sheet and are attached to a desired site of the human body using the adhesive sheet.

[0007] However, because these microneedle products are manufactured in patch form, they can only be used on limited areas of the human body, and furthermore, if the adhesive strength of the adhesive sheet is weak, the effect is very poor. [Overview of the project] [Problems that the invention aims to solve]

[0008] This invention was made to solve the above problems and aims to provide microneedle particles that can be used over a wide area of ​​the human body and can be used with cosmetics and the like regardless of their adhesive strength. [Means for solving the problem]

[0009] The object of the present invention described above is achieved by a method for producing microneedle particles, comprising the steps of: providing a particle aggregate in which a plurality of microneedle particles are formed on the upper surface of a first film; and separating the microneedle particles from the particle aggregate, wherein the step of separating the microneedle particles from the particle aggregate includes a step of weakening the adhesive force between the first film and the microneedle particles.

[0010] Here, the first film may be composed of a water-soluble film. Furthermore, the first film contains polyvinylpyrrolidone, polyvinyl alcohol, cellulose polymer, dextran, gelatin, glycerin, polyethylene glycol, polysorbate, propylene glycol, povidone, carbomer, ghatti gum, guar gum, glucomannan, glucosamine, dammer resin, rennet casein, locust bean gum, microfibrillated cellulose, psyllium seed gum, xanthan gum, arabino galactan, gum arabic, alginic acid, gelatin, gellan gum, carrageenan, karaya gum, curdlan, chitosan, chitin, tara gum, and tamarind gum. gum, tragacanth gum, furcelleran, pectin or pullulan, hydroxypropyl methylcellulose (HPMC), hydroxyalkylcellulose, ethyl hydroxyethylcellulose, alkylcellulose, gluten, soy polysaccharides, polacrilin potassium, sodium starch glycolate, crospovidone, croscarmellose sodium, bentonite, hydroxypropyl starch, sodium carboxymethylcellulose, sodium alginate, sodium lauryl sulfateIt may consist of one or more of the following: Lauryl Sulfate, Silicic anhydride, Hydroxypropyl cellulose, Polyvinyl acetate, Amylose, Sodium hydrogen carbonate, Amylopectin, Sodium polyphosphate, and Aluminum magnesium silicate.

[0011] Furthermore, the particle aggregate may further include a second film that adheres to the lower surface of the first film.

[0012] Furthermore, the second film may be composed of a hydrophobic film or a hydrophilic film. For example, the second film may be composed of one or more materials selected from high-density polyethylene (HDPE), polystyrene (PS), polypropylene (PP), polyethylene terephthalate (PET), and polyethylene naphthalate (PEN).

[0013] Furthermore, the adhesive strength between the first film and the microneedle particles may be higher than the adhesive strength between the second film and the microneedle particles.

[0014] On the other hand, the step of weakening the adhesion between the first film and the microneedle particles may include treating the particle aggregate with a solvent to dissolve the first film or to swell the first film.

[0015] In this case, the solvent does not need to dissolve the microneedle particles.

[0016] For example, the solvent may consist of one or more substances selected from distilled water, ethanol, acetone, oleyl alcohol, isoparaffin, and dipropylene glycol.

[0017] On the other hand, when the first film is swollen with the solvent, the process may further include a step of separating the microneedle particles from the first film by applying a lateral force to the microneedle particles.

[0018] Furthermore, when the first film is dissolved in the solvent, the process may further include the steps of filtering and extracting the microneedle particles from the solvent, and drying the microneedle particles.

[0019] On the other hand, when treating the particle aggregate with the solvent, the particle aggregate may be treated using the solvent in a liquid state, or the solvent may be vaporized and the particle aggregate may be treated with the solvent in a gaseous state.

[0020] Furthermore, the above-mentioned objectives of the present invention may be achieved by microneedle particles manufactured by the method for manufacturing microneedle particles described above. [Effects of the Invention]

[0021] According to the present invention having the above configuration, when microneedle particles are used together with cosmetics, etc., they can be used over a wide area of ​​the human body, and can also be used regardless of adhesive strength. [Brief explanation of the drawing]

[0022] [Figure 1]It is a flowchart showing a method for manufacturing micro-needle particles according to an embodiment of the present invention. [Figure 2] It is a diagram showing a particle aggregate according to an embodiment of the present invention. [Figure 3] It is a conceptual diagram showing the process of treating a particle aggregate according to an embodiment with a solvent in a liquid state. [Figure 4] It is a diagram showing the process of swelling a first film from a particle aggregate to separate micro-needle particles after solvent treatment. [Figure 5] It is a diagram showing the state where the first film is dissolved from the particle aggregate and micro-needle particles are separated after solvent treatment. [Figure 6] It is a diagram showing a particle aggregate according to another embodiment of the present invention. [Figure 7] It is a diagram showing the process of manufacturing a particle aggregate according to another embodiment. [Figure 8] It is a conceptual diagram showing the process of treating a particle aggregate according to another embodiment with a solvent in a liquid state. [Figure 9] It is a diagram showing the process of swelling a first film from a particle aggregate to separate micro-needle particles after treating the particle aggregate with a solvent according to another embodiment. [Figure 10] It is a diagram showing the state where the first film is dissolved from the particle aggregate and micro-needle particles are separated after treating the particle aggregate with a solvent according to another embodiment. [Figure 11] It is a schematic diagram showing an apparatus for supplying and treating a solvent by vaporizing it to a particle aggregate. [Figure 12] It is a conceptual diagram showing the use process of a cosmetic containing micro-needle particles according to the present invention.

Embodiments for Carrying Out the Invention

[0023] Hereinafter, referring to the drawings, a method for manufacturing micro-needle particles according to an embodiment of the present invention will be described in detail.

[0024] Figure 1 is a flowchart showing a method for manufacturing microneedle particles according to one embodiment of the present invention, and Figure 2 is a diagram showing a particle assembly 100 according to one embodiment of the present invention.

[0025] Referring to Figures 1 and 2, the method for manufacturing the microneedle particles may include the steps of providing a particle aggregate 100 in which a plurality of microneedle particles 14 are formed on the upper surface of a first film 12 (S110), and separating the microneedle particles 14 from the particle aggregate 100 (S130).

[0026] Here, the particle aggregate 100 can be defined as a structure in which microneedle particles 14 to be manufactured in the present invention are attached to a film support layer 20 including the first film 12.

[0027] For example, the particle aggregate 100 may include a film support layer 20 containing a first film 12 made of a water-soluble film, and a plurality of biodegradable microneedle particles 14 formed on the film support layer 20.

[0028] Preferably, the first film 12 is composed of a substance that dissolves or swells in a predetermined solvent when separating the microneedle particles 14 from the particle aggregate 100, as will be described later.

[0029] The first film 12 contains polyvinylpyrrolidone, polyvinyl alcohol, cellulose polymer, dextran, gelatin, glycerin, polyethylene glycol, polysorbate, propylene glycol, povidone, carbomer, ghatti gum, guar gum, glucomannan, glucosamine, dammer resin, rennet casein, locust bean gum, microfibrillated cellulose, psyllium seed gum, xanthan gum, arabinogalactan, gum arabic, alginic acid, gelatin, gellan gum, carrageenan, karaya gum, curdlan, chitosan, chitin, tara gum, and tamarind gum. gum, tragacanth gum, furcelleran, pectin or pullulan, hydroxypropyl methylcellulose (HPMC), hydroxyalkylcellulose, ethyl hydroxyethylcellulose, alkylcellulose, gluten, soy polysaccharides, polacrilin potassium, sodium starch glycolate, crospovidone, croscarmellose sodium, bentonite, hydroxypropyl starch, sodium carboxymethylcellulose, sodium alginate, sodium lauryl sulfate, anhydrous silicic acidIt may consist of one or more of the following selected materials: anhydride, hydroxypropyl cellulose, polyvinyl acetate, amylose, sodium hydrogen carbonate, amylopectin, sodium polyphosphate, and aluminum magnesium silicate.

[0030] On the other hand, the microneedle particles 14 may have a shape in which the diameter or area of ​​the lower part is larger than the diameter or area of ​​the upper part. That is, the microneedle particles 14 may have a conical or pyramidal shape with a pointed upper part, or a shape with a pointed tip at the top. In this way, if the microneedle particles 14 have a pointed tip at the top, they can be penetrated more effectively into the skin of the human body when used in cosmetics, etc., as will be described later.

[0031] For example, the microneedle particles 14 may be made of a substance that is biocompatible and biodegradable and dissolves when inserted into the skin.

[0032] Examples include hyaluronic acid and its salts, polyvinylpyrrolidone, polyvinyl alcohol, cellulose polymer, dextran, gelatin, glycerin, polyethylene glycol, polysorbate, propylene glycol, povidone, carbomer, ghatti gum, guar gum, glucomannan, glucosamine, dammer resin, rennet casein, locust bean gum, microfibrillated cellulose, psyllium seed gum, xanthan gum, arabino galactan, gum arabic, alginic acid, gelatin, gellan gum, carrageenan, karaya gum, curdlan, chitosan, chitin, tara gum, and tamarind gum. You may also use materials such as gum, tragacanth gum, furcelleran, pectin or pullulan, hydroxypropyl methylcellulose, hydroxyalkylcellulose, and carboxymethylcellulose.

[0033] The aforementioned particle aggregate 100 can be manufactured by various known methods, including the mold method. Therefore, the method for manufacturing the particle aggregate 100 is not particularly limited.

[0034] Figure 3 is a conceptual diagram showing the process of treating the aforementioned particle aggregate 100 with solvent 32. For example, Figure 3 shows the process of treating the particle aggregate 100 using solvent 32 in a liquid state.

[0035] Referring to Figures 2 and 3, the step of separating the microneedle particles 14 may include a step of weakening the adhesive force between the first film 12 and the microneedle particles 14.

[0036] For example, the step of weakening the adhesive force between the first film 12 and the microneedle particles 14 may include the step of dissolving the first film 12 or swelling the first film 12.

[0037] First, a method for swelling the first film 12 will be described.

[0038] In this embodiment, the aforementioned particle aggregate 100 is treated with a predetermined solvent 32, and the solvent 32 causes the first film 12 of the particle aggregate 100 to swell, thereby weakening the adhesive force between the first film 12 and the microneedle particles 14.

[0039] In this case, the solvent 32 may be selected as a substance that swells the first film 12 but does not dissolve the microneedle particles 14.

[0040] For example, the solvent 32 may consist of one or more substances selected from distilled water, ethanol, acetone, oleyl alcohol, isoparaffin, and dipropylene glycol. The aforementioned solvent has the property of swelling the first film 12 well while not dissolving the microneedle particles 14 made of the aforementioned components or substances.

[0041] However, if the solvent 32 is composed of an aqueous ethanol solution, the microneedle particles 14 can dissolve in the solvent 32 if the concentration of ethanol in the aqueous ethanol solution is less than about 70% (i.e., if the concentration of water is greater than about 30%). Therefore, the concentration of ethanol in the aqueous ethanol solution is preferably 70% or higher.

[0042] Therefore, as shown in Figure 3, the particle aggregate 100 can be supplied to a housing 30 or tank containing a solvent 32 in a predetermined liquid state, and immersed in the solvent 32. The particle aggregate 100 is immersed in the solvent 32 and treated by the solvent 32.

[0043] In this case, as described above, the solvent 32 can cause the first film 12 of the particle aggregate 100 to swell.

[0044] Figure 4 shows the process of separating microneedle particles 14 from particle aggregate 100 after solvent treatment.

[0045] Figure 4(A) shows the particle aggregate 100 before solvent treatment, and Figure 4(B) shows the particle aggregate 100 after solvent treatment.

[0046] As shown in Figure 4(B), the particle aggregate 100 before solvent treatment swells due to the swelling of the first film 12, as shown in Figure 4(A). When the first film 12 swells, its surface area increases, and the adhesive force between the microneedle particles 14 and the first film 12 becomes weaker than before the first film 12 swelled.

[0047] As described above, the procedure may further include the step of separating the microneedle particles 14 from the first film 12 by applying a lateral force to the microneedle particles 14, following the step of weakening the adhesive force between the first film 12 and the microneedle particles 14.

[0048] As shown in Figure 4(C), when a lateral force F is applied to the microneedle particles 14, the microneedle particles 14 are easily separated from the first film 12, and as shown in Figure 4(D), the microneedle particles 14 can be separated from the first film 12 and extracted.

[0049] The lateral force F applied to the microneedle particles 14 can be applied manually by an operator or automatically by a mechanical device.

[0050] After extracting the microneedle particles using the method described above, the extracted microneedle particles are dried.

[0051] In conclusion, the microneedle particles 14 manufactured by the aforementioned method can be incorporated into cosmetics such as lotions and creams and used in the future.

[0052] On the other hand, Figure 5 is a conceptual diagram showing the process of separating the microneedle particles 14 from the particle aggregate 100 by dissolving the first film 12 in the step of weakening the adhesive force between the first film 12 and the microneedle particles 14.

[0053] Referring to Figure 5, in the step of separating the microneedle particles, the particle aggregate 100 is treated with a solvent 32 that dissolves the first film 12 but does not dissolve the microneedle particles 14, thereby separating the microneedle particles 14 from the film support layer 20.

[0054] In other words, in this embodiment, the first film 12 is dissolved with a predetermined solvent 32 to separate the microneedle particles 14 from the film support layer 20. In this case, the solvent 32 can be selected to dissolve only the first film 12 and not the microneedle particles 14.

[0055] In this case, the solvent 32 dissolves the first film 12 of the particle aggregate 100, and the microneedle particles 14 remain in the solvent 32, as shown in Figure 5.

[0056] Next, the microneedle particles 14 are filtered and extracted from the solvent 32, and the microneedle particles 14 are dried.

[0057] On the other hand, Figure 6 shows a particle aggregate 100' according to another embodiment of the present invention.

[0058] Referring to Figure 6, in the particle aggregate 100' according to this embodiment, the aforementioned film support layer 20' may further include the second film 10.

[0059] In this case, the second film 10 may be provided on the lower surface of the first film 12. That is, the first film 12 may be formed on the upper surface of the second film 10 by a method such as coating.

[0060] The second film 10 can serve as a support sheet or support film for the particle aggregate 100.

[0061] Furthermore, the second film 10 may be composed of a hydrophobic film, but is not limited to that, and may also be composed of a hydrophilic film.

[0062] For example, the second film 10 may consist of one or more materials selected from high-density polyethylene (HDPE), polystyrene (PS), polypropylene (PP), polyethylene terephthalate (PET), and polyethylene naphthalate (PEN).

[0063] Furthermore, the first film 12 can be selected such that the adhesive strength between the first film 12 and the microneedle particles 14 is higher than the adhesive strength between the second film 10 and the microneedle particles 14. The adhesive strength between the first film 12 and the microneedle particles 14 will be described in detail in the step of manufacturing the microneedle particles 14.

[0064] Figure 7 shows the steps for manufacturing the particle aggregate 100' according to the other embodiments described above.

[0065] Referring to Figure 7, the step of providing the particle aggregate 100' may include first providing a pair of the second films 10, forming a pair of film support layers 20' by providing a first film 12 formed on each of the pair of second films 10 to enhance adhesion with the microneedle particles 14, and spotting a biodegradable viscous substance 13 on at least one of the first films 12 of the pair of film support layers 20'.

[0066] The pair of second films 10 serve as support films for the film support layer 20' of the particle aggregate 100'.

[0067] The second film 10 may be provided, for example, on a pair of substrates (not shown). In this case, the second film 10 may be provided coated and dried on the substrates, or it may be provided in sheet form.

[0068] On the other hand, a first film 12 is provided on each of the pair of second films 10. The first film 12 can be coated onto the second film 10, thereby forming a film layer.

[0069] If the first film 12 is omitted, the viscous substance 13 forming the microneedle particles 14 is directly spotted onto the second film 10. In this case, the adhesive force between the viscous substance 13 and the second film 10 is weak, so the viscous substance 13 cannot form a tip during the tensioning step described later. That is, since the viscous substance 13 can be separated from the second film 10 during the tensioning step, the film support layer 20' cannot be sufficiently separated, resulting in the formation of microneedle particles where the upper and lower viscous substances 13 are adhered to each other. Such microneedle particles have a so-called hourglass shape, which reduces their penetration effect into the skin.

[0070] Therefore, in this embodiment, the first film 12 is provided on the second film 10. In this case, the first film 12 can be selected such that the adhesive strength between the first film 12 and the microneedle particles 14 is higher than the adhesive strength between the second film 10 and the microneedle particles 14.

[0071] Furthermore, the adhesive force between the first film 12 and the microneedle particles 14 can be determined to such an extent that the viscous substance 13 can form a pointed end when the viscous substance 13 is pulled by separating the pair of film support layers 20' in the tensioning step described later.

[0072] On the other hand, Figure 7(A) illustrates, but is not limited to, the application of the viscous substance 13 to all of the first films 12 of the pair of film support layers 20'. For example, it is also possible to apply the viscous substance 13 to only one of the first films 12 of the pair of film support layers 20'.

[0073] Next, the pair of film support layers 20' are moved relative to each other so that they are closer together (Figure 7(A)), causing the viscous substance 13 to come into contact with the first film 12 between the first film 12 of the pair of film support layers 20', and separating the pair of film support layers 20' to pull the viscous substance 13 (Figure 7(B)).

[0074] In this case, as described above, the adhesive force between the viscous substance 13 and the first film 12 can be determined to such an extent that the viscous substance 13 can form a tip, or to an extent greater than that.

[0075] Next, the viscous substance 13 is solidified, separating the pair of film support layers 20', and forming microneedle particles 14 on the first film 12 of the pair of film support layers 20'.

[0076] In this case, the viscous substance 13 can be solidified by methods such as blowing air. After the viscous substance 13 has solidified sufficiently, if the film support layer 20' is further separated, the viscous substances 13 that were connected to each other are separated, and microneedle particles 14 having pointed ends are formed (Figure 7(C)).

[0077] Subsequently, as shown in Figure 8, the particle aggregate 100' is treated with a liquid solvent 32, and then, as shown in Figure 9, the microneedle particles 14 are separated from the particle aggregate 100'.

[0078] The particle aggregate 100' shown in Figure 9(A) before solvent treatment swells after solvent treatment, as shown in Figure 9(B), due to the swelling of the first film 12. When the first film 12 swells, its surface area increases, and the adhesive force between the microneedle particles 14 and the first film 12 becomes weaker compared to before the first film 12 swelled.

[0079] Next, as shown in Figure 9(C), when a lateral force F is applied to the microneedle particles 14, the microneedle particles 14 are easily separated from the first film 12, and as shown in Figure 9(D), the microneedle particles 14 can be separated from the first film 12 and extracted.

[0080] The lateral force F applied to the microneedle particles 14 can be applied manually by an operator or automatically by a mechanical device.

[0081] After extracting the microneedle particles using the method described above, the extracted microneedle particles are dried.

[0082] On the other hand, Figure 10 is a conceptual diagram showing the process of dissolving the first film 12 in a particle aggregate 100' according to another embodiment, thereby separating the microneedle particles 14 from the particle aggregate 100'.

[0083] In other words, the particle aggregate 100' is treated with a solvent 32 that dissolves the first film 12 but does not dissolve the microneedle particles 14. Therefore, it is possible to separate the microneedle particles 14 from the film support layer 20.

[0084] In this case, the solvent 32 dissolves the first film 12 of the particle aggregate 100', and as shown in Figure 10, the microneedle particles 14 and the second film 10 are separated and remain in the solvent 32.

[0085] On the other hand, after the microneedle particles 14 and the second film 10 are separated, the second film 10 is removed from the solvent 32, and the microneedle particles 14 are extracted by filtration. Since the second film 10 remains in the solvent 32, it can be easily removed.

[0086] On the other hand, since the microneedle particles 14 remain in the solvent 32, the solvent 32 is filtered to extract the microneedle particles 14. Next, the microneedle particles are dried.

[0087] On the other hand, Figure 11 is a schematic diagram showing an apparatus for processing particle aggregates by supplying them with a vaporized solvent. Figure 11(A) shows an apparatus for processing particle aggregate 100 with a gaseous solvent according to one embodiment, and Figure 11(B) shows an apparatus for processing particle aggregate 100' with a gaseous solvent according to another embodiment.

[0088] Referring to Figure 11, in order to treat the particle assemblies 100 and 100' with a vaporized solvent or a solvent in a gaseous state, a sealed space capable of containing the particle assemblies 100 and 100' is required.

[0089] In Figure 11, a chamber 1000 is used to provide a containment space 1010 for housing the particle assemblies 100 and 100' inside the chamber 1000. Although shown as chamber 1000 in the drawing, it is not limited to this, and any sealed structure that can accommodate the vaporized solvent and the particle assemblies 100 and 100' may be used.

[0090] On the other hand, although not shown in the drawings, the chamber 1000 may also include an opening (not shown) for introducing the particle assemblies 100, 100' into the containment space 1010, and a door (not shown) for opening and closing the opening.

[0091] Furthermore, a support plate 1100 on which the particle assemblies 100 and 100' are placed may be provided in the containment space 1010 inside the chamber 1000. The support plate 1100 can be realized as various structures on which the particle assemblies 100 and 100' are placed or which support the particle assemblies 100 and 100'.

[0092] On the other hand, a solvent supply unit 1200 capable of supplying vaporized solvent or a gaseous solvent into the chamber 1000 may be provided on one side of the chamber 1000.

[0093] For example, the solvent supply unit 1200 can vaporize ethanol and supply it into the chamber 1000. The amount of vaporized solvent supplied by the solvent supply unit 1200, the supply time, etc., can be adjusted as appropriate.

[0094] As shown in Figure 11, when the particle assemblies 100 and 100' are treated with a vaporized solvent, the first film 12 dissolves or swells in the particle assemblies 100 and 100', weakening the adhesion between the first film 12 and the microneedle particles 140, allowing them to separate. This has been explained previously, so a redundant explanation will be omitted.

[0095] Figure 12 is a conceptual diagram illustrating the process of using cosmetics containing microneedle particles 14.

[0096] As shown in Figure 12(A), when a user applies and rubs the cosmetic product onto their skin, the microneedle particles 14 contained in the cosmetic product can penetrate the skin, as shown in Figure 12(B).

[0097] In particular, the microneedle particles 14 according to this embodiment have a pointed shape, which provides excellent penetration into the skin. Since the microneedle particles 14 are made of a biocompatible and biodegradable substance, they do not harm the human body even when they penetrate the skin.

[0098] Thus, when the microneedle particles 14 penetrate the skin, cosmetic ingredients can also penetrate together with or in accordance with the microneedle particles 14, as shown in Figure 12(C).

[0099] On the other hand, it is also possible to incorporate a functional substance into the microneedle particles 14 themselves. For example, in the step of manufacturing the particle aggregate 100 described above, the functional substance can be included together with the viscous substance that forms the microneedle particles 14.

[0100] Examples of such functional substances include wrinkle-improving substances and moisture-supplying substances, and the present invention is not limited to any particular substance.

[0101] Although preferred embodiments of the present invention have been described above, those skilled in the art will be able to modify and change the present invention in various ways without departing from the spirit and scope of the invention as described in the claims below. Therefore, if a modified implementation basically includes the elements of the claims of the present invention, it should be understood that it falls within the technical scope of the present invention. [Explanation of symbols]

[0102] 10. Film No. 2 12 First Film 14 Microneedle Particles 20 Film support layer 32 Solvents 100 particle aggregates

Claims

1. The steps include providing a particle aggregate in which a plurality of microneedle particles are formed on the upper surface of a first film, A step of separating the microneedle particles from the particle aggregate, Includes, The step of separating the microneedle particles from the particle aggregate includes the step of weakening the adhesive force between the first film and the microneedle particles. A method for producing microneedle particles, characterized in that the step of weakening the adhesive force between the first film and the microneedle particles includes the step of treating the particle aggregate with a solvent to dissolve the first film or to swell the first film.

2. The method for producing microneedle particles according to claim 1, characterized in that the first film is made of a water-soluble film.

3. The first film is, Polyvinylpyrrolidone, polyvinyl alcohol, cellulose polymer, dextran, gelatin, glycerin, polyethylene glycol, polysorbate, propylene glycol, povidone, carbomer, ghatti gum, guar gum, glucomannan, glucosamine, dammer gum, rennet casein, locust bean gum, microfibrous cellulose, psyllium seed gum, xanthan gum, arabinogalactan, gum arabic, alginic acid, gelatin, gellan gum (gum), carrageenan, karaya gum, curdlan, chitosan, chitin, tara gum, tamarind gum, tragacanth gum, furcelleran, pectin or pullulan, hydroxypropyl methylcellulose (HPMC), hydroxyalkylcellulose, ethyl hydroxyethylcellulose, alkylcellulose, gluten, soy polysaccharides, polarin potassium, sodium starch Glycolate, crospovidone, croscarmellose sodium, bentonite, hydroxypropyl starch, sodium carboxymethylcellulose Carboxymethyl Cellulose, sodium alginate, sodium lauryl sulfate, anhydrous silicic acid, hydroxypropyl cellulose, polyvinyl acetate, amylose, sodium hydroxypropyl carbonate, amylopectin, sodium polyphosphate, and aluminum magnesium silicate. A method for producing microneedle particles according to claim 2, characterized by comprising one or more mixtures selected from silicate.

4. The method for producing microneedle particles according to claim 1, characterized in that the particle aggregate further comprises a second film attached to the lower surface of the first film.

5. The method for producing microneedle particles according to claim 4, characterized in that the second film is composed of a hydrophobic film or a hydrophilic film.

6. The aforementioned second film is A method for producing microneedle particles according to claim 4, characterized by comprising one or more materials selected from high-density polyethylene (HDPE), polystyrene (PS), polypropylene (PP), polyethylene terephthalate (PET), and polyethylene naphthalate (PEN).

7. The method for producing microneedle particles according to claim 4, characterized in that the adhesive strength between the first film and the microneedle particles is higher than the adhesive strength between the second film and the microneedle particles.

8. The method for producing microneedle particles according to claim 1, characterized in that the solvent does not dissolve the microneedle particles.

9. The aforementioned solvent is A method for producing microneedle particles according to claim 1, characterized in that it comprises one or more substances selected from distilled water, ethanol, acetone, oleyl alcohol, isoparaffin, and dipropylene glycol.

10. When swelling the first film with the solvent, The method for producing microneedle particles according to claim 1, further comprising the step of separating the microneedle particles from the first film by applying a lateral force to the microneedle particles.

11. When dissolving the first film with the aforementioned solvent, The steps include filtering and extracting the microneedle particles from the solvent, A method for producing microneedle particles according to claim 1, further comprising the step of drying the microneedle particles.

12. When treating the particle aggregate with the aforementioned solvent, A method for producing microneedle particles according to claim 1, characterized by treating the particle aggregate with the solvent in a liquid state, or by vaporizing the solvent and treating the particle aggregate with the solvent in a gaseous state.

13. Microneedle particles manufactured by the method for manufacturing microneedle particles according to any one of claims 1 to 12.

Images